Drug intelligence / Profile preview

AUT5

Development stage: Preclinical
Lead developer: Autifony Therapeutics
Modality: Small Molecules

Overview

AUT5 (also known as EX15) is a preclinical-stage, selective small molecule positive allosteric modulator (PAM) of Kv3 voltage-gated potassium channels, specifically targeting the Kv3.1 (KCNC1) and Kv3.2 (KCNC2) subtypes. Developed by Autifony Therapeutics, AUT5 binds to a unique pocket at the extracellular inter-subunit interface between the voltage-sensing and pore domains, stabilized by the extracellular turret region. By promoting the open state of these channels, AUT5 enhances the high-frequency repetitive firing of fast-spiking GABAergic interneurons. It is utilized as a research tool to investigate therapeutic strategies for central nervous system disorders, including Alzheimer's disease, schizophrenia, Fragile X syndrome, and epilepsy.

Other names: EX-15EX15EX 15

Targets

KCNC1 (Kv3.1)KCNC2 (Potassium voltage-gated channel subfamily C member 2)

Beyond the preview

Go deeper on AUT5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUT5.